iifl-logo

Unichem Laboratories Ltd Board Meeting

688.2
(-0.91%)
Apr 2, 2025|11:49:50 AM

Unichem Labs. CORPORATE ACTIONS

02/04/2024calendar-icon
02/04/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting28 Mar 202528 Mar 2025
Outcome of Board Meeting
Board Meeting1 Mar 20251 Mar 2025
Outcome of Board Meeting - Sale of property
Board Meeting6 Feb 202514 Jan 2025
UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31 2024. Unaudited Financial Results (Consolidated & Standalone) for the quarter and nine-months ended 31st December 2024 Included Mr. Uttkarsh Patil, Chief Manufacturing officer - Formulations, as a senior Management Personnel under SEBI LODR Regulations with effect from 6th February 2025 (As Per BSE Announcement dated on 06.02.2025)
Board Meeting13 Nov 202425 Oct 2024
UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Unaudited Financial Results for the quarter ended September 30 2024. Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2024 (As Per BSE Announcement Dated on: 13/11/2024)
Board Meeting30 Sep 202423 Sep 2024
UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/09/2024 inter alia to consider and approve integration and consolidation of the generics formulations business in the US market. Purchase of Product approvals and all goodwill associated with Nine (9) ANDAs owned by Bayshore Pharmaceuticals LLC, USA for USD 2,650,000 by the Company and Purchase of USA generics formulations business as a going concern through slump sale ./ transfer of business by Unichem Pharmaceuticals (USA) Inc through assets purchase agreements for USD 10,000,000. (As per BSE Announcement dated on 30/09/2024) Board approved entering into following agreements with Bayshore Pharmaceuticals LLC, USA (Bayshore USA) (wholly owned step-down subsidiary of Ipca Laboratories Limited, Companys holding company) for: a. Purchase all of rights, title and interest in the Product approvals and all goodwill associated with Nine (9) ANDAs owned by Bayshore USA for US dollars two million six hundred fifty thousand ($ 2,650,000) through asset purchase agreement subject to required consents and approvals, if any; and b. Unichem Pharmaceuticals (USA) Inc (Unichem USA), a wholly owned subsidiary of the Company, to purchase USA generics formulations marketing/distribution business of Bayshore USA (Step-down subsidiary of parent company Ipca Laboratories Ltd) as a going concern through slump sale/transfer of entire business (debt free) and all goodwill associated with the business through asset purchase agreement for US dollars ten million ($10,000,000) (As Per BSE Bulletin Dated on 04.10.2024)
Board Meeting8 Aug 202426 Jul 2024
UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve Unaudited financial results (standalone & consolidated) for the quarter ended 30th June 2024. PFA herewith Outcome of Board Meeting (As Per BSE Announcement Dated on 08.08.2024)
Board Meeting22 May 20249 May 2024
UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2024 inter alia to consider and approve Financial results for quarter and year ended March 31 2024 Outcome of Board Meeting PFA herewith financial results for the quarter and year ended 31st March 2024 (As Per BSE Announcement dated on 22.05.2024)

Unichem Labs.: Related News

Unichem Labs Q3 Profit Drops 20.5% YoY, Revenue Up 14.5%
6 Feb 2025|10:48 PM

Revenue increased by 14.5% to ₹533 crore from ₹466 crore the previous year.

Read More
Unichem Labs plans to consolidate US generic formulations bizz
23 Sep 2024|03:02 PM

Bayshore Pharmaceuticals is a 100% subsidiary of Unichem Laboratories' parent firm, Ipca Laboratories Ltd.

Read More
Unichem Labs Goa facility gets 5 observations from USFDA
16 Jul 2024|11:11 AM

According to the corporation, the observations have no influence on business continuity or supplies to the US market.

Read More
Top 10 stocks for today - 16th July, 2024
16 Jul 2024|08:47 AM

Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Birla Estates, Lupin, etc.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.